# KangaBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kangabio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.kangabio.com
- Latest round: Angel (Dec 31, 2021)
- Investors on record: 1

## About

Established in 2021 and based in Shanghai, China, KangaBio is a biotechnology company focused on providing innovative medicines to meet unmet clinical medical needs. The company's founder and CEO, Dr. Weidong Jiang, previously co-founded Shanghai Fohong Hanlin Biotechnology Co. in 2009, which led to its successful listing on the Hong Kong Stock Exchange in 2019. Currently, the company has formed R&D teams in the direction of protein drug early discovery and drug process development, etc. In June 2023, the company closed a round of pre-series A funding.

The company focuses on the development of safe and effective oncology drugs to meet unmet clinical needs in oncology therapeutic areas by developing a new generation of immune agonists and multi-specific antibodies based on globally innovative prodrug protein molecular technologies. Its current pipeline includes KGX101, a modified and optimized cytokine IL12 prodrug molecule, and KGX103, a cytokine prodrug molecule targeted to treat solid and metastatic tumors, etc.

## Funding rounds

- Angel, Dec 31, 2021 — TF Capital

## Investors

- TF Capital — Angel